Back to top
more

Cardinal Health (CAH)

(Delayed Data from NYSE)

$94.16 USD

94.16
1,891,045

-0.30 (-0.32%)

Updated Jul 12, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Retain Patterson Companies (PDCO) Stock Now

by Zacks Equity Research

Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.

Why You Should Buy The Cooper Companies (COO) Stock Now

by Zacks Equity Research

The Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to drive the top line further.

NextGen (NXGN) Behavioral Health Suite to Focus on Mental Health

by Zacks Equity Research

NextGen's (NXGN) Behavioral Health Suite is expected to offer better access to care and improve patient outcomes.

Revvity's (PKI) Q1 Earnings Top, '23 View Below Expectations

by Zacks Equity Research

Revvity's (PKI) first-quarter results reflect the impact of transition following divestment of AES business. While earnings outpace estimates, sales miss the same.

Fresenius Medical (FMS) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Fresenius Medical's (FMS) first-quarter revenues benefit from strong performances across all segments, especially the North America and Asia-Pacific regions. However, rising costs hurt margins.

Masimo (MASI) Q1 Earnings Surpass Estimates, Margins Down

by Zacks Equity Research

Masimo's (MASI) robust product shipments and continued strength in its healthcare business drive its Q1 sales.

DaVita (DVA) Tops Q1 Earnings Estimates, Ups FY23 EPS View

by Zacks Equity Research

DaVita's (DVA) robust revenues in both segments drive its first-quarter performance.

Shockwave Medical (SWAV) Q1 Earnings Top, Revenues Surge Y/Y

by Zacks Equity Research

Shockwave Medical's (SWAV) first-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.

McKesson (MCK) Q4 Earnings Beat Estimates, U.S. Sales Strong

by Zacks Equity Research

McKesson's (MCK) fiscal fourth-quarter 2023 results benefit from growth in the United States. Divestment hurt the International segment.

Avanos (AVNS) Q1 Earnings and Revenues Fall Shy of Estimates

by Zacks Equity Research

Despite strength in Avanos' (AVNS) Chronic Care segment, its overall first-quarter results reflect soft performances.

AMN Healthcare (AMN) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

AMN Healthcare's (AMN) dismal results in all its segments led to a soft overall Q1 performance.

Inogen (INGN) Q1 Earnings Beat Estimates, Revenues Lag

by Zacks Equity Research

Despite higher domestic business-to-business sales and rental revenues, Inogen's (INGN) overall first-quarter results reflect soft performances.

Should Value Investors Buy AmerisourceBergen (ABC) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Cardinal Health (CAH) Beats on Q3 Earnings, Ups '23 EPS View

by Zacks Equity Research

Cardinal Health's (CAH) fiscal third-quarter results benefit from the Pharmaceutical segment's solid performance.

Cardinal Health (CAH) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Cardinal (CAH) delivered earnings and revenue surprises of 17.57% and 1.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

BD (BDX) Gears Up for Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have benefited Q2 sales.

Shaun Pruitt headshot

2 Medical Stocks to Buy Before Earnings

by Shaun Pruitt

Cardinal Health (CAH) and Ligand Pharmaceuticals (LGND) are two healthcare companies that investors certainly want to watch going into their quarterly reports.

What Awaits Lantheus Holdings (LNTH) This Earnings Season?

by Zacks Equity Research

Lantheus Holdings' (LNTH) first-quarter results are likely to reflect solid top-line results on the back of robust product adoption.

Is a Beat Likely for Cardinal Health (CAH) in Q3 Earnings?

by Zacks Equity Research

Cardinal Health's (CAH) third-quarter fiscal 2023 results are expected to reflect solid performance in the Pharmaceutical segment. However, inflationary pressure is likely to have continued.

Autolus (AUTL) Selects Cardinal Health for Cell Therapy Supply

by Zacks Equity Research

Autolus (AUTL) partners with Cardinal Health to bring next-generation CAR-T cell therapies to the market and revolutionize cancer treatment.

McKesson (MCK) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

McKesson (MCK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cardinal Health (CAH) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Cardinal Health (CAH) closed at $82.10 in the latest trading session, marking a +0.02% move from the prior day.

Cardinal (CAH) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

Cardinal (CAH) possesses solid growth attributes, which could help it handily outperform the market.

AMN Healthcare (AMN) to Post Q1 Earnings: What's in the Cards?

by Zacks Equity Research

AMN Healthcare's (AMN) first-quarter results are likely to reflect soft demand across its segments.

Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Boston Scientific (BSX) and Cardinal Health (CAH) have performed compared to their sector so far this year.